Latest Product News
Havn Life Sciences To Supply Psychedelics to Clinical Studies Focused on Veterans and PTSD
Havn Life Sciences Inc. a biotechnology company, announced it has signed a Memorandum of Agreement (“MOA”) with the international veterans organization, Heroic Hearts Project.
CYBIN Signs Definitive Agreement to Acquire Adelia Therapeutics
Cybin Inc. today announced the signing of a definitive agreement to acquire 100% of the shares in Adelia Therapeutics Inc.
BioMed X Institute Completes First Research Project in Neuroscience
BioMed X announces the successful completion of its first joint research project with Boehringer Ingelheim in neuroscience.
Fujirebio Diagnostics Files 510(k) with FDA For Lumipulse G β-Amyloid Ratio
Fujirebio Diagnostics, Inc. today announced that it has filed its Lumipulse® G β-Amyloid Ratio (1-42/1-40) in vitro diagnostic test with the FDA.
MOBILion and International Research Team are Awarded Grant for Research in Parkinson's Disease
MOBILion Systems is collaborating with an international research team to identify alterations in the metabolism of selective glycosphingolipids in the brain.
Movers and Shakers in Biobusiness Report
The seventh annual Movers and Shakers in BioBusiness report highlights 30 examples of resourceful leaders in the UK bioscience sector.
PerkinElmer Launches No-Wash Immunoassay for Neuroscience Disease and Therapeutics Research
PerkinElmer, Inc., today launched the life science industry’s first no-wash Ubiquitin phosphorylation at Serine 65 immunoassay that is aimed at helping scientists discover new therapeutic candidates earlier in the disease cycle.
Impel Neuropharma Presents Data for the 2020 Migraine Trust Virtual Symposium
Impel NeuroPharma announced that it has presented patient-reported outcomes data from the Company’s pivotal Phase 3, open-label study “STOP 301” of INP104 (dihydroergotamine mesylate) or DHE using the company’s proprietary POD technology, for the treatment of acute migraine in an oral presentation at the Migraine Trust Virtual Symposium (MTIS) to be held from October 3-9, 2020.
CZI Awards $4.5M to Advance Innovative Approaches to Fighting Neurodegenerative Diseases
The Chan Zuckerberg Initiative has announced $4.5 million in funding to support 30 pairs of researchers to collaborate and apply novel approaches for gaining greater insight into neurodegenerative disorders.
Cobra Biologics Delivers Final Plasmids for Production of CG01 in CombiGene's Epilepsy Project
The milestone in the project paves the way for production of novel gene therapy drug candidate designed to treat drug-resistant focal epilepsy.